EWTX - CIK 0001710072
The table below shows Edgewise Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $42.65M | $37.48M | $33.56M | $36.76M | $32.22M | $30.68M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $11.46M |
| $9.38M |
| $9.05M |
| $9.20M |
| $8.21M |
| $7.43M |
| Operating income | -$54.12M | -$46.86M | -$42.61M | -$45.96M | -$40.43M | -$38.11M |
| Income tax | - | - | - | - | - | - |
| Net income | -$49.01M | -$40.67M | -$36.12M | -$40.80M | -$34.13M | -$31.50M |
| EPS (diluted) | -$0.46 | -$0.39 | -$0.34 | -$0.43 | -$0.36 | -$0.34 |